药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Mecasermin
Urelumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Urelumab.
Mecasermin
Visilizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Visilizumab.
Mecasermin
Gantenerumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Gantenerumab.
Mecasermin
Benralizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Benralizumab.
Mecasermin
Anifrolumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Anifrolumab.
Mecasermin
Rilotumumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Rilotumumab.
Mecasermin
Crenezumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Crenezumab.
Mecasermin
Avelumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Avelumab.
Mecasermin
Varlilumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Varlilumab.
Mecasermin
Lebrikizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Lebrikizumab.
Mecasermin
Vadastuximab Talirine
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Vadastuximab Talirine.
Mecasermin
Romosozumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Romosozumab.
Mecasermin
Landogrozumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Landogrozumab.
Mecasermin
Seribantumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Seribantumab.
Mecasermin
Ligelizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ligelizumab.
Mecasermin
Ublituximab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ublituximab.
Mecasermin
Emibetuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Emibetuzumab.
Mecasermin
Dalotuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dalotuzumab.
Mecasermin
Lampalizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Lampalizumab.
Mecasermin
Tremelimumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tremelimumab.